Abstract
CAR-T therapy has emerged as a revolutionary approach in the battle against cancer. By leveraging the body's own immune system, this technique harnesses the power of T cells, which are genetically engineered to recognize specific antigens found on cancer cells. The procedure involves isolating lymphocytes from patients, followed by laboratory-based genetic modifications to infuse them with distinct CAR genes. Once these enhanced CAR-T cells are reintroduced into the patient, they actively target and neutralize cancer cells. However, the journey of CAR-T therapy is not without challenges. The selection of the right antigen is paramount, as an incorrect choice can lead to unintended consequences. Moreover, the application of this therapy in solid tumors presents its own set of complexities. This review aims to shed light on the clinical potential of CAR-T therapy, the obstacles faced in the realm of solid tumor treatment, and the ongoing research endeavors to refine and improve this promising therapeutic strategy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
